Acceptance of the respiratory syncytial virus infant monoclonal antibody nirsevimab among post-partum women in Italy

Silvia Angelillo, Grazia Miraglia del Giudice, Giorgia Della Polla, Italo Francesco Angelillo, The Collaborative Working Group · 2026

Read Acceptance of the respiratory syncytial virus infant monoclonal antibody nirsevimab among post-partum women in Italy by Silvia Angelillo, Grazia Miraglia del Giudice, Giorgia Della Polla, Italo Francesco Angelillo, The Collaborative Working Group (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13271307.txt.

Description

Silvia Angelillo is lead author of a 2026 cross-sectional survey on acceptance of nirsevimab among new mothers in Italy. Nirsevimab is an antibody shot given to infants. It protects them against respiratory syncytial virus, a common cause of serious chest infection in babies. The survey covered women who had recently given birth in southern Italy.

Between March and April 2025, 476 women completed interviews, a 96.6 percent response rate. Half judged the antibody very useful for protecting their newborn, and 86.5 percent had immunised their baby. Mothers who trusted the vaccination information they received, and those who had not relied on the internet or social media, were more likely to accept. The authors call for education built into pregnancy care.

Catalog record

CREATORSilvia Angelillo, Grazia Miraglia del Giudice, Giorgia Della Polla, Italo Francesco Angelillo, The Collaborative Working Group
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37910
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13271307

Browse the full library · About the Tower of Babel